HANGZHOU TIGERMED CONSULTING (300347) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose 15.23% YoY to RMB 5.792bn, while attributable net loss was RMB 272.0m; adjusted attributable net income increased 38.08% to RMB 450.1m.

• Q3 revenue grew 17.38% YoY to RMB 2.084bn; attributable net income fell 77.85% to RMB 141.1m, while adjusted attributable net income rose 49.62% to RMB 172.3m.

Financial highlights

• 9M total operating costs were RMB 5.217bn, versus RMB 4.560bn a year earlier; 9M net income was a loss of RMB 124.1m, versus income of RMB 1.092bn.

• 9M investment income fell to RMB 29.3m from RMB 440.2m; fair-value changes swung to a RMB 597.0m loss from a RMB 323.2m gain.

• 9M operating cash flow was RMB 771.3m, up 4.29% YoY; cash and cash equivalents ended at RMB 2.040bn.

• Total assets were RMB 27.986bn at Sep. 30, down 1.32% from year-end; equity attributable to shareholders was RMB 19.638bn, down 6.31%.

Key financial ratios and metrics

• Q3 basic and diluted EPS were RMB 0.17, down 77.14% YoY; 9M basic and diluted EPS were negative RMB 0.32, down 126.89%.

• Weighted average ROE was 0.72% for Q3, down 2.31 percentage points YoY, and -1.33% for 9M, down 6.22 percentage points.